WEST LAFAYETTE, Ind., Nov. 10, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates and companion imaging diagnostics for personalized therapy, today announced financial results for the third quarter ending September 30, 2011, and provided an operational update.
